PFD Capital Partners announced that Regeneration Biomedical, Inc. received FDA Fast Track designation for RB-ADSC, its investigational autologous adipose-derived stem cell therapy for mild to moderate Alzheimer’s disease, and selected multiple Phase IIa clinical trial sites to support a larger randomized, placebo-controlled evaluation of the treatment. The release explains that RB-ADSC uses Wnt-activated adipose-derived stem cells delivered directly into the brain’s ventricular system through an implanted Ommaya reservoir, while emphasizing that the therapy remains investigational and is not FDA-approved. The Phase IIa trial is expected to assess safety, tolerability, repeat dosing, CSF biomarkers, cognitive performance, and functional outcomes, with selected sites including Hoag Hospital Newport Beach, Baptist Hospital of Miami, Boca Raton Regional Hospital, Carilion Roanoke Memorial Hospital, Pacific Neuroscience Institute, Tampa General Hospital, and UC Davis Health. PFD frames these milestones as meaningful clinical and regulatory progress within its PFDSMRH3002 medical technology strategy, while repeatedly cautioning that Fast Track designation and site selection do not establish safety, efficacy, approval, commercialization potential, or investment success.